Background: This phase I study was designed to determine the optimal dosages of a novel repetitive high-dose therapy regimen for patients with metastatic breast cancer (MBC).
Introduction

Patients and methods
Although the results of phase II studies, phase III studies and registry data of autologous bone marrow and peripheral blood progenitor cells (PBPC) transplantation for metastatic breast cancer (MBC) are promising, approximately 80% or more of these highly-selected patients relapse [1, 2] . Tumour growth models predict that the delivery of multiple cycles of high-dose therapy (HDT), rather than a single cycle, may be a more effective way of further increasing chemotherapy dose-intensity (reviewed in [3] ). We therefore initiated this phase I study examining the tolerability of a novel combination of HDT supported by PBPCs, delivered every 28 days for three cycles in patients with MBC. The design of this protocol focused on the development of a regimen where patients could be followed predominantly as outpatients (i.e., not requiring parenteral nutrition or opiate analgesia for gastrointestinal toxicity). We selected two alkylating agents active in MBC for our regimen, ifosfamide and thiotepa [4] [5] [6] in combination with conventional-dose paclitaxel [7] .
Collection of PBPCs
Patients underwent mobilization of PBPC using an alkylator-based regimen; ifosfamide (6 g/m 2 ) with mesna (n = 16) or cyclophosphamide (1.5 g/m 2 ; « = 3) followed by daily subcutaneous G-CSF (filgrastim: 10 ug/kg/day). The alkylating agent was combined with either doxorubicin (50 mg/m 2 ) or paclitaxel (175 mg/m 2 over three hours; Anzatax®, F.H. Faulding Pharmaceuticals, Adelaide, Australia) depending on prior cumulative anthracycline exposure. Four patients had PBPCs mobilized with filgrastim alone (10 ug/kg/day).
The apheresis procedure and assessment of autograft haematological parameters has been described previously [8, 9] . Apheresis was continued until sufficient cells to support three separate cycles of HDT had been collected i.e., a minimum target of 4.5 x 10 6 /kg (a minimum of 1.5 x 10 6 /kg CD34+ cells for each of the three cycles of HDT). To ensure uniformity, each collection was divided into three separate bags, so that each re-infusion contained PBPCs collected from each day of apheresis.
High-dose therapy
High-dose therapy was administered according to the following schedule and cycles were planned for every 28 days; on day -4 patients commenced a 24-hour infusion of ifosfamide with mesna. Thiotepa was administered over one hour on days -4 , -3 , -2 . Two hours after the administration of the thiotepa on day -2, paclitaxel (175 mg/m Abbreviations: RTA -renal tubular acidosis; GI -gastrointestinal. a One patient withdrawn after cycle 1 and one patient withdrawn after cycle 2 because of asthenia. b One patient elected to discontinue after cycle 2 because of asthenia, one patient withdrawn after cycle 2 because of delayed platelet recovery.
Maximum tolerated dose
Cohorts of four patients were enrolled at sequential dose levels (Table 1) Additional patients were accrued at a given dose level if a patient developed toxicity and did not complete all three cycles (see toxicity below). The maximum tolerated dose (MTD) was denned when two or more patients developed dose-limiting toxicity (DLT) defined as NCI grade 4 non-haematological toxicity (excluding alopecia) or grade 3 neurological, cardiac or renal toxicity, or when two or more patients were unable to complete three cycles of high-dose therapy because of haematological toxicity
Results
Patient characteristics
Twenty-three patients were enrolled with a median age of 44 years (range 32-58) and median time from initial diagnosis of breast cancer to transplant of 15 months (range 2.6-53). The majority of patients had metastatic disease (n -19) with a median of two sites involved (range 1-4) with 14 patients having visceral metastatic disease. Three patients had locally advanced disease, all of whom were refractory to conventional-dose neoadjuvant therapy. Seventy percent of patients had received a prior anthracycline. A total of 12 patients (52%) were resistant to conventional-dose chemotherapy. Twelve patients (52%) had received taxane-containing regimens prior to the high-dose regimen (paclitaxel = 10, docetaxel = 2).
Apheresis collections
All patients enrolled in the study obtained sufficient 
Dose intensity and non-haematopoietic toxicity
Of the 23 patients undergoing high-dose therapy, 59 of the planned 69 treatment cycles were delivered. Fifteen patients completed all three cycles (total cycles = 45), six completed two cycles (total cycles = 12) and two completed only one cycle (total cycles = 2). Treatment was delivered in the majority of patients every 28 days (range 24-38 days).
Dose-limiting toxicities are detailed in Table 1 . There was one treatment-related death due to intractable gastrointestinal bleeding at level 5. Other relevant, but non-dose-limiting toxicities were grade 2 reversible interstitial pneumonitis (IP) in two patients (levels 2 & 4), thiotepa induced rash and peripheral neuropathy. Both patients with IP responded to steroid treatment and were re-treated at the same dose. Three patients at level 5 had dose-limiting toxicity and therefore the recommended dose for phase II studies is ifosfamide (10 g/m 2 ), thiotepa (350 mg/m 2 ) and paclitaxel (175 mg/m 2 ).
Haematological toxicity/recovery
For all 59 cycles, the median time to ANC > 1.0 x 10 9 /l was 10 days (range 8-28) with no slowing of neutrophil recovery over consecutive cycles (P = 0.8760; repeated measures ANOVA). G-CSF was required for a median of 11 days (range 6-32 days) for each cycle. Febrile neutropenia occurred following 67% of all cycles and when it occurred, lasted for a median of three days. Admission to hospital was required following 78% of cycles with a median stay in hospital of five days (range 2-20 days). The reason for admission into hospital was febrile neutropenia in 84% of cases.
The median time to platelets greater than 20 x 10 9 /l, 50 x l0 9 /l and 100 x 1O 9 /1 was 13 days (range 8-38), 18 days (range 10-40) and 25 days (range 13-152), respectively. There was significant slowing in platelet recovery to > 100 x 1O 9 /1 between cycle 1 and the subsequent cycles (P = 0.028). A median of two platelet transfusions and two packed red blood cell transfusions were required following each cycle of treatment.
Discussion
Other investigators have explored repetitive high-dose therapy for breast cancer by attempting to repeat or combine recognized 'single-transplant' regimens or modifying existing regimens by selective reductions in drug doses. Not unexpectedly this has resulted in wide variation in reported toxicities [10] [11] [12] . These results emphasize the need for careful dose-escalation studies of repetitive high-dose therapy. Indeed, no formal phase I studies of repetitive high-dose therapy have been published to date.
Non-haematological toxicity determined the MTD of our regimen. Although we were able to deliver this therapy three-times (every 28 days) in the majority of patients (71%), our study demonstrates that the use of high-dose ifosfamide for treatment of MBC is problematic with the dose limiting toxicities of renal-tubular acidosis, encephalopathy, enterocolitis and mucositis all being ifosfamide-related.
The major thiotepa-related toxicities observed were mucositis, interstitial pneumonitis and skin rash. Importantly, although the maximum cumulative dose of thiotepa in this study was 1050 mg/m 2 , the typical neurological toxicity of a 'dementia-like syndrome' was not observed. However, formal neuropsychiatric testing was not performed and subtle defects may not have been detected.
Although the re-admission rate was high, the length of stay in hospital was relatively short at five days and patients treated at level 4 or below did not require opiate analgesia or parenteral nutrition for mucositis. This is of some importance as the regimen achieves substantial dose-intensity while maintaining patients in the outpatient setting for the majority of their treatment.
We conclude that repeated cycles of high-dose ifosfamide, thiotepa and paclitaxel can be delivered in the majority of patients and this combination warrants further investigation. The recommended doses for phase II and III studies are ifosfamide (10 g/m 2 ), thiotepa (350 mg/m 2 ) and paclitaxel (175 mg/m 2 ).
